According to filings with the U.S. Securities and Exchange Commission, Cell Source is raising $3,905,134.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Itamar Shimrat played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Cell Source
Cell Source is a biotechnology company focused on developing cell therapy treatments based on the management of immune tolerance. Our patented Veto Cell technology is the centerpiece of treatment protocols that represent major breakthroughs in immune system management safe and selective tolerizing of immune response. Our technology addresses one of the most fundamental challenges in the field of immunology: how to tune immune response so that it tolerates specific desirable foreign cells and tissue while continuing to attack all other potential threats.

To learn more about Cell Source, visit http://cell-source.com/

Contact:
Itamar Shimrat, President and Chief Executive Officer
616-416-7896
https://www.linkedin.com/in/itamar-shimrat-4a96258/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.